ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
September 13, 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight
September 10, 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
BVI to Launch New SERENITY and SERENITY Toric Premium Monofocal IOLs, Delivering an Extended Range of Vision to More Patients, at the 2024 ESCRS
September 03, 2024 06:45 ET
|
BVI Medical
Non-diffractive IOLs SERENITY and SERENITY Toric are the second generation of BVI’s original, innovative ISOPURE premium monofocal IOL launched in 2019.These IOLs incorporate patented ISOFOCAL optic...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
August 27, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
[Latest] US Eyewear Market Size/Share Worth USD 30,322.1 Million by 2033 at a 5.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 31, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, July 31, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Eyewear Market Size, Trends and Insights By Product Type (Prescription...
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
May 15, 2024 16:01 ET
|
Eyenovia, Inc.
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the...
Cepham’s Luteye Centers on Cellular Senescence to Protect Aging Eyes
May 01, 2024 08:30 ET
|
Cepham
Cepham announces the launch of Luteye to combat the effects of aging on eyes.
NANO MAGIC UPDATE
April 24, 2024 09:00 ET
|
Nano Magic, Inc.
Madison Heights, Michigan, April 24, 2024 (GLOBE NEWSWIRE) -- Nano Magic, Inc. (OTC: NMGX) (“Nano Magic” or the “Company”), a leader in innovative nanotechnology powered cleaning solutions,...
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
April 03, 2024 07:00 ET
|
Eyenovia, Inc.
Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting,...
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 18, 2024 16:05 ET
|
Eyenovia, Inc.
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to...